Our primary objective is to develop an easily assayable germline-based panel of biomarkers to aid in selecting prostate cancer patients for management with active surveillance. As a secondary objective, we tend to incorporate potentially promising…
ID
Source
Brief title
Condition
- Reproductive neoplasms male malignant and unspecified
- Prostatic disorders (excl infections and inflammations)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
To test SNP*s that are related to the diagnosis and prognosis of aggressive
prostate cancer. Relevant SNP*s as detected by the Prostate SPORE Working Group
and the International Consortium for Prostate Cancer Genetics will be tested.
Secondary outcome
Assess the possibilities to enhance existing risk stratification tools with
genomic based information to improve patient selection for an active
surveillance management strategy.
Background summary
Active surveillance for prostate cancer is an accepted alternative to radical
prostatectomy or radiotherapy for low-risk potentially indolent prostate
cancers. The selection of patients for an active surveillance management
strategy is not yet ideal as it is not known which prostate cancers will become
aggressive and which will stay indolent. Recent advances in genomic research
have made it possible to identify genomic based biomarkers for aggressive
prostate cancer.
Study objective
Our primary objective is to develop an easily assayable germline-based panel of
biomarkers to aid in selecting prostate cancer patients for management with
active surveillance. As a secondary objective, we tend to incorporate
potentially promising DNA-based markers for aggressive prostate cancer into
risk stratification tools.
Study design
This is an observational study.
Study burden and risks
One single blood draw during a one-time visit to the screening office at the
Department of Urology, Erasmus MC. There is no benefit for the current PRIAS
patients that decide to participate. The study does, however, generate
important information for men that have to decide on following an active
surveillance strategy in the future.
Wytemaweg 80
Rotterdam 3015 CN
NL
Wytemaweg 80
Rotterdam 3015 CN
NL
Listed location countries
Age
Inclusion criteria
- Signed informed consent for the PRIAS study.
- Men 60 to 80 years of age.
Exclusion criteria
- Patients with a Gleason score out of the *3+3 range.
- Patients with more than 3 cores involved with cancer.
- Withdrawn informed consent from the PRIAS study.;Patients that do not want to be informed about any potential life threatening abnormalities found in their DNA, cannot participate in the study.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL55163.078.15 |